TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05308394

Intervention type: OTHER
Intervention: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.
Description: Each participant will provide a blood and fecal sample.

Intervention type: OTHER
Intervention: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.
Description: Each participant will provide a blood and fecal sample.

Intervention type: OTHER
Intervention: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.
Description: Each participant will provide a blood and fecal sample.

Intervention type: OTHER
Intervention: No experimental intervention will take place - the study is cross-sectional. Each participant will provide biological samples.
Description: Each participant will provide a blood and fecal sample.
Study: NCT04121806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: UC intervention diet
Description: The treatment diet has been designed based on the literature with the goal of influencing the biodiversity and density of the microbiome. All food through the duration of the 8 week dietary intervention period of the study will be provided to the treatment arm study participants.
Study: NCT05925153

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT04799158

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Orally via capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally via capsules
Study: NCT06145178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SPYVAC01
Description: Novel vaccine SPYVLP01
Study: NCT05863767

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baduanjin sequential therapy
Description: Baduanjin sequential therapy consists of eight different movements including the preparatory phase till final movement (gathering the energy). The session will account for 30 minutes twice a day for four weeks.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional Therapy
Description: Neck stretches Arm circles Triceps stretch Calf stretch Forward step up Strengthening exercises Every exercise 5 repetitions three times a day
Study: NCT05833841

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Surface Electromyography and Video fluoroscopy
Description: Surface EMG of three muscle groups (masseter, submental, and infrahyoid) and video fluoroscopy with Omnipaque
Study: NCT05439330

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI of teeth and surrounding structures
Description: included above
Study: NCT04040465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Participants will be categorized into 3 BMI groups and will be randomly given various doses of aspirin to compare effectiveness and create a dosing regimen.
Study: NCT05843032

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3D ultrasound, MRI, resected specimen examination by surgeon
Description: 3D ultrasound and MR scanning of the resected tongue tumor will be performed. The resected surgical specimen will also be examined by the surgeon to assess the margins. The accuracy of the margin assessment by 3D ultrasound, MRI, and surgeon examination will be evaluated by correlating the results to the final histopathology findings.
Study: NCT03674775

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: DART QI Program Participation
Description: Antibiotic prescribing data will be collected at multiple time points both before and after the initiation of the intervention.
Study: NCT04962035

Intervention type: OTHER
Intervention: Neurocognitive Follow-up
Description: Standard clinical and parent-reported outcomes on cognitive development, temperament and overall health conditions.
Study: NCT06355804

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical activity condition
Description: Participants will receive a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide behavioral strategies such as information on the benefits of physical activity, goal setting and monitoring, for increasing and maintaining physical activity levels.~  * Throughout the 16-week period, the investigators will ask participants to wear a Fitbit and record step count into a logbook daily for tracking physical activity.~ * The newsletter will be emailed to participants weekly throughout the program. The newsletters include knowledge, skills, and resources related to physical activity in the early stages of MS.~* The program also involves 7 1-on-1 coaching chats with a coach to guide participants through the program and navigate challenges. These chats are conducted over Zoom and generally last about 15 - 30 minutes each. These sessions will not be recorded.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist condition
Description: Participants will receive access to a remote-delivered physical activity program for 16 weeks that includes access to electronic newsletters and regular chats over Zoom with a behavioral coach:~* The newsletters provide information on the benefits of physical activity, goal setting and monitoring, and other behavioral strategies for increasing and maintaining physical activity levels.~  * The newsletter will be emailed to participants weekly throughout the program.~ * Content on the newsletter includes knowledge and skills related to physical activity in the early stages of MS, text of individuals with MS discussing their experiences, web links, worksheets, and brochures.~* The program also involves 7 one-on-one video coaching chats with a behavioral coach to guide participants through the program and navigate challenges. These chats are conducted face- to-face over Zoom and generally last about 15 - 30 minutes each. The investigators do not record these sessions.
Study: NCT05435950

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sono-Intruments
Description: Spirecut's single use, pre-CE Sono-Instruments (SI) allow the percutaneous treatment of Carpal Tunnel (CT) syndrome and Trigger Finger/thumb (TF) under sonography (instead of open or endoscopic approach).~Two models will be assessed:~* The Carpal Tunnel Sono-Instrument® (CT-SI), for CT syndrome release, by progressively cutting the transverse carpal ligament.~* The Trigger Finger Sono-Instrument® (TF-SI), for TF release by progressively cutting the A1 annual pulley.
Study: NCT06405763

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Snodgrass repair
Description: A relaxing incision is made in the midline by using scalpel or scissors~A 6 F stent is passed into the bladder. The neourethra is closed

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Snodgrass repair with graft
Description: A relaxing incision is made in the midline by using scalpel or scissors In grafted Snodgrass repairA free graft was measured and harvested from the inner prepuce and was defatted and sutured onto the incised urethral plate The graft was sutured overlying the incision line A 6 F stent is passed into the bladder. The neourethra is closed
Study: NCT06375486

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivonescimab（AK112，a PD-1/VEGF bispecific antibody）
Description: All enrolled subjects will receive Ivonescimab（AK112，a PD-1/VEGF bispecific antibody，20mg/kg Q3W) in combination with HAIC (utilizing the FOLFOX chemotherapy regimen)
Study: NCT05422183

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Envafolimab
Description: 400mg，sc，d1，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: 8 mg(BW\<60 kg) OR 12 mg(BW≥60 kg)，po，qd，d1-21，Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VP-16
Description: 50 mg/d, po,d1-14，Q3W
Study: NCT06064955

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Support
Description: Former caregivers will be paired with a current caregiver based on a similar personal attribute (e.g., relationship to care recipient). Each pair will complete at least five virtual face-to-face (video) interactions and at least 10 other interactions either via phone call, email, or text messaging over the 6-month time period.
Study: NCT04964856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ERAS exercise
Description: Take ERAS exercise twice a day from hospitalization to 30 days after surgery

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No ERAS exercise
Description: Don't take ERAS exercise in perioperative period
Study: NCT05410093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: Take Resveratrol (250mg, NuMedica, FDA approved) at a dose of 250mg per day for three months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin E
Description: Take vitamin E at a dose of 100 mg per day for three months
Study: NCT06470477

Intervention type: DRUG
Intervention: Guideline-based treatment
Description: Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.

Intervention type: DRUG
Intervention: Guideline-based treatment
Description: Guideline-based treatment includes anti-platelet therapy, control of vascular risk factors, and so on.
Study: NCT06052527

Intervention type: OTHER
Intervention: Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning
Description: A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning

Intervention type: OTHER
Intervention: Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning
Description: A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning

Intervention type: OTHER
Intervention: Autonomous Treatment System for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza Based on Machine Learning
Description: A novel treatment recommendation system for Covid-19, Post-Acute Sequelae of SARS-CoV-2 Infection and Influenza, which is based on machine learning
Study: NCT05976776

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Childbirth and Parenthood Preparation Education
Description: The Childbirth and Parenthood Preparation Education program will be applied to the experimental group for a period of 1 month (each week, once a week in total four sessions).
Study: NCT04765917

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected physical Therapy program
Description: -Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Strengthening exercises for weakened muscles in upper and lower limbs muscle.~* Strengthening exercises for back and abdominal muscles.~* Stretching exercises for tight muscles in upper and lower limbs.~* Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Jumping in place and jumping a board.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Selected physical Therapy program
Description: -Facilitation of balance reactions from standing position including: Standing on one leg, weight shifting from standing position, stoop and recover from standing, squat from standing, standing on balance board and pushing the child in different directions.~* Facilitation of counterpoising mechanism through instructing the child to kick ball from standing position as well as catching and throwing ball with his hands.~* Strengthening exercises for weakened muscles in upper and lower limbs muscle.~* Strengthening exercises for back and abdominal muscles.~* Stretching exercises for tight muscles in upper and lower limbs.~* Gait training activities for correction of gait pattern including: walking on balance beam, walking on balance board, walking on uneven surface, walking using different obstacles (rolls, wedges, stepper) and walking up and down stairs.~* Jumping in place and jumping a board.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor imagery training program
Description: As a preparation each child will be shown a video of 5 minutes of normal movements.~They will be positioned in a comfortable position. The screen is in the child's visual field. Children will be asked to close their eyes and imagine they will perform the physically practiced task for 10 minutes, similar to one shown in the video. Sequence of the task will be verbally explained to the child for better recalling of sensations in muscles during the movements. During the entire exercise schedule child's attention will be focused on the position, and movement of their body, on proprioceptive inputs coming from the leg muscles and on the tactile sensations of foot floor contact.~Thereafter, the child will be asked to perform the sequence of tasks, rehearsed mentally for 20 minutes.
Study: NCT06395883

Intervention type: DRUG
Intervention: Glucocorticoid Effect
Description: Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Intervention type: DRUG
Intervention: Glucocorticoid Effect
Description: Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Intervention type: DRUG
Intervention: Glucocorticoid Effect
Description: Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.

Intervention type: DRUG
Intervention: Glucocorticoid Effect
Description: Patients with or without glucocorticoid treatment will be observed regarding the level of bone turnover markers (P1NP and CTX1) every 4 weeks til 6 months after the last glucocorticoid dose.
Study: NCT06220487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone, Olverembatinib, Blinatumomab, Chidamide
Description: Phase One. Induction Consolidation, for 1 year. 1.1 Pretreatment ×1 cycle. Prednisone，1mg/kg/d, from day 1 to 14;~1.2 Induction Therapy × 1 cycle. A: OlverembAtinib (at a dose of 40 mg Qod), from day 8 to 42. B: Blinatumomab (at a dose of 28 μg per day), from day 15 to 28. C: Chidamide (at a dose of 10 mg Qod), from day 9 to 41.~1.3 Consolidation Block × 5 cycles. A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42. B: Blinatumomab (at a dose of 28 μg perday) was administered from day 1 to 14. C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Two. Maintenance Therapy, for 3 years. 2.1 A: Olverembatinib (at a dose of 40 mg Qod) was administered from day 1 to 42.~C: Chidamide (at a dose of 10 mg Qod) was administered from day 14 to 41.~Phase Three. Follow-up, for 5 years.
Study: NCT06435546

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood samples
Description: Ferritin, Transferrin Saturation (TSAT), Serum iron, Haemoglobin, Albumin

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adherence to anti-cancer therapies questionnaires
Description: GIRERD questionnaire, AdOT questionnaire, Use of social networks and alternatives and complementary medicines using patient questionnaire, EORTC QLQC30, HADS, MNA, MSPSS
Study: NCT05137002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CIN-107
Description: CIN-107 tablets by mouth once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets by mouth once daily
Study: NCT06485622

Intervention type: PROCEDURE
Intervention: open bypass group
Description: After heparinization, the target artery is clamped above and below the anastomosis. The target artery is dissected along the anterior wall, calcium portions or mural thrombus are removed. Graft (autologous or prosthetic graft) is cut obliquely and anastomosis suturing starts with distal angle. Next stage is tunnel creating for graft conduction.

Intervention type: PROCEDURE
Intervention: bare metal stent group
Description: Bare metal stent implantation during the index procedure.

Intervention type: PROCEDURE
Intervention: plain old balloon angioplasty group
Description: Only plain old balloon was used during the index procedure.

Intervention type: PROCEDURE
Intervention: drug-coated balloon group
Description: Drug-coated balloon was used during the index procedure.

Intervention type: PROCEDURE
Intervention: directional atherectomy group
Description: Directional atherectomy (with or without drug-coated balloon) during the index procedure.

Intervention type: PROCEDURE
Intervention: hybrid repair group
Description: Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery. Arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological). Endovascular revascularization followed.
Study: NCT05840549

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TURP
Description: TURP is an operation which can be performed under a general / regional anaesthetic. A cystoscope is passed into the urethra meatus, along the length of the urethra to the level of the prostate. The obstructing prostate lobes are resected using mono polar or bipolar energy to create a channel for improved urinary flow. Haemostasis is achieved by coagulation followed by insertion of a catheter for irrigation post procedure. Generally, patients stay for 1-2 nights post operatively. On the day of discharge the catheter is removed.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: UroLift
Description: UroLift (Neotract) is a NICE-approved alternative to TURP that can be performed under local anaesthetic, sedation or general anaesthetic. The system comprises of two single-use components, a delivery device and an implant. The implant is made of a nitinol capsular tab, a polyethylene terephthalate monofilament and a stainless-steel end-piece. Again, a modified cystoscope is passed into the urethral meatus, along the length of the urethra to the level of the prostate. The delivery device deploys the implants into the prostate to 'pin' back the lobes of the prostate to create a channel for improved flow. Typically, 2-4 implants are used per procedure. Nine out of ten patients do not require a catheter post procedure
Study: NCT03667443

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol + folic a. + α-lactalbumin
Description: 3 months of treatment

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Myo-inositol + folic a.
Description: 3 months of treatment
Study: NCT05309330

Intervention type: OTHER
Intervention: No Intervention
Description: This is a non-interventional study.
Study: NCT04805164

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Corticotomy and use of the bone substitute : Cerament-G device.
Description: Corticotomy and Cerament-G device

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Corticotomy
Description: Corticotomy
Study: NCT06376760

Intervention type: OTHER
Intervention: No interventions, it is a observational study
Description: No interventions, this study is to compare the dosage requirement of intravenous anesthetic drug during digestive endoscopy between insomnia group and normal sleep group.

Intervention type: OTHER
Intervention: No interventions, it is a observational study
Description: No interventions, this study is to compare the dosage requirement of intravenous anesthetic drug during digestive endoscopy between insomnia group and normal sleep group.